Skip to main content

Home/ OARS funding Aging/ Group items tagged biomed

Rss Feed Group items tagged

MiamiOH OARS

Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center: ... - 0 views

  •  
    The purpose of this FOA is to support the development of a Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center that will organize activities and provide research resources for clinician-investigators across the United States who are focusing their careers on aging research. This FOA is intended to build upon the substantial investments made by NIA through the GEMSSTAR program and related career development efforts by supporting expanded activities to reach a broader community of clinician-investigators. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance transdisciplinary research projects in aging. Ultimately, the Clin-STAR Coordinating Center is intended to provide a multi-faceted national research platform leading to improved patient-centered care for older adults across specialties and disciplines.
MiamiOH OARS

RFA-AG-19-011: Integrative Omics to Enhance Therapeutics Development for Healthy Aging ... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person-specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls.
MiamiOH OARS

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) - 0 views

  •  
    The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.
MiamiOH OARS

PA-18-738: Age-related Microbiota Changes and their Implications in Chronic Disease Pre... - 0 views

  •  
    The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.
MiamiOH OARS

RFA-HL-19-016: Technologies for Healthy Independent Living for Heart, Lung, Blood and S... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults.
MiamiOH OARS

Program to Accelerate Clinical Trials | Alzheimer's Drug Discovery Foundation - 0 views

  •  
    Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies.
    The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects.
    Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.
MiamiOH OARS

Lewy Body Dementia Center Without Walls (CWOW) (U54 Clinical Trial Not Allowed) - 0 views

  •  

    This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.
MiamiOH OARS

Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (U0... - 0 views

  •  
    The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.
MiamiOH OARS

PA-18-572: Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optio... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons.
    Also listed under R01& R03
MiamiOH OARS

RFA-AG-18-029: Interdisciplinary Research to Understand the Complex Biology of Resilien... - 0 views

  •  
    To date, the pursuit of disease-modifying therapy development for Alzheimer's disease (AD) has been primarily informed by the study of diseased individuals, often by comparing genomic and other molecular, cellular and physiologic features in AD cases and controls. This has proven extremely challenging given the disease's heterogeneity and its multifactorial etiology. There is a growing appreciation that the development of effective treatment and prevention for complex diseases such as AD can benefit from gaining a much deeper understanding of what it means to be well and which genomic, epigenomic, environmental, social, and behavioral factors promote wellness and protection against disease.

MiamiOH OARS

RFA-NS-18-018: BRAIN Initiative: Biology and Biophysics of Neural Stimulation (R01 - Cl... - 0 views

  •  
    The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to treat and prevent brain disorders.

MiamiOH OARS

T1 Translational Research on Aging: Small Business Innovation Awards (R43/R44 Clinical ... - 0 views

  •  
    The involvement of small businesses in translational aging research could substantially hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to encourage a greater involvement by small businesses through the SBIR mechanism in transforming scientific advances in aging research into novel devices, products, health care practices and programs that will benefit the lives of older adults.
    For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical or basic behavioral and social research findings towards the development of new strategies for prevention and treatment of age-related pathologies. T1 translational research approaches could include the development of new research tools or improving existing technologies to diagnose, prevent or treat age-related conditions, functional decline and disability.
MiamiOH OARS

PA-18-396: Mentored Quantitative Research Development Award (Parent K25 - No Independen... - 0 views

  •  
    The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease.  The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

MiamiOH OARS

PA-18-369: Mentored Research Scientist Development Award (Parent K01 -Independent Clini... - 0 views

  •  
    The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.
MiamiOH OARS

Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseas... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, aging, and mitochondrial disease transmission to offspring. The overarching goal is to gain fundamental insight into the role of mitochondria and long-term consequences of their dysfunction in the oocyte, and to develop therapeutic or alternative approaches to treat mitochondrial dysfunction for improving oocyte quality and competency, and health of the resultant offspring. It is anticipated that the results from studies supported by this FOA will provide women, suffering from infertility or subfertility and other illnesses due to mitochondrial dysfunction, practical approaches to enhance their fertility and the well-being of their offspring. This funding opportunity announcement encourages innovative and high-risk/impact studies that may lead to breakthrough in mitochondrial function, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in understanding and treatment of mitochondrial dysfunction.
MiamiOH OARS

Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adu... - 0 views

  •  
    Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
MiamiOH OARS

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical ... - 0 views

  •  
    The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.
MiamiOH OARS

Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional) - 0 views

  •  
    This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.
MiamiOH OARS

Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementi... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
MiamiOH OARS

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive ... - 0 views

  •  

    This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
1 - 20 of 122 Next › Last »
Showing 20 items per page